Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Conference News TCT 2023

MitraClip G4 Data Impress, but Some Question the Reproducibility: EXPAND G4

Yael L. Maxwell

November 02, 2023

News Conference News TCT 2020

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

L.A. McKeown

October 17, 2020

News Conference News TCT 2020

Global EXPAND: Next-Gen MitraClip Cuts MR, Boosts QoL at 1 Year

L.A. McKeown

October 16, 2020

Presentation TCT 2019

DMR: EVEREST II Was a Decade Ago; Have MitraClip Techniques and Outcomes Improved?

Presenter: Stephen Little

September 26, 2019

Presentation TCT 2017

How to Interpret Noninferiority Trials (eg, ABSORB III, EVEREST II, and Others)

Presenter: Roxana Mehran, Robert W. Yeh, Sanjay Kaul

October 30, 2017

News Conference News TCT 2015

Experts Debate Mitral Valve Repair, Replacement for Intermediate-Risk Patients

October 12, 2015

Presentation TCT 2015

Five-Year Randomized EVEREST II Results: Where MitraClip Shined (and Where It Didnt)

Presenter: Stephan Baldus, Scott Lim, Ted E. Feldman

October 11, 2015

Presentation TCT 2014

Outcomes Following Percutaneous Reduction of Significant Mitral Regurgitation in EVEREST II High Risk Patients Who Were Symptomatic Despite Cardiac Resynchronization Therapy

Presenter: Saibal Kar

September 16, 2014

Presentation TCT 2014

Final 5-Year EVEREST II Results: Perspectives on What We Might Have Done Differently

Presenter: Olaf Franzen, James B. Hermiller Jr, Michael J. Rinaldi, Ted E. Feldman

September 13, 2014

Presentation TCT 2014

Anatomic Criteria for the MitraClip: Are the Everest Criteria Just a Start?

Presenter: Olaf Franzen, James B. Hermiller Jr, Michael J. Rinaldi, Saibal Kar

September 13, 2014

Presentation TCT 2014

TCT 788: Outcomes Following Percutaneous Reduction of Significant Mitral Regurgitation in EVEREST II High-Risk Patients Who Were Symptomatic Despite Cardiac Resynchronization Therapy

Presenter: Blase A. Carabello, Allan Schwartz, Charles J. Davidson, Saibal Kar

September 13, 2014

News Conference News TCT 2013

ACCESS-EUROPE, EVEREST II Data Support MitraClip in MR

October 30, 2013

Presentation TCT 2013

TCT-85. Ventricular and Atrial Remodeling after the Percutaneous MitraClip: 4 year Follow-up Data from the EVEREST II Randomized Controlled Trial

Presenter: Atif Qasim

October 29, 2013

Presentation TCT 2013

TCT-89. Percutaneous Leaflet Therapy of Severe Primary Mitral Regurgitation: Totality of Evidence From the EVEREST II Randomized, Continued Access, and High Risk Clinical...

Presenter: Saibal Kar

October 29, 2013

Presentation TCT 2013

The EVEREST II Randomized Controlled Trial (RCT): Three Year Outcomes

Presenter: Ted Feldman, Elyse Foster, Mansoor Qureshi, Brian Whisenant, John Williams, Donald Glower, Laura Mauri

January 31, 2013

Presentation TCT 2013

Cost Effectiveness of the MitraClip® Compared with Mitral Valve Surgery: 12-month Results from the EVEREST II Randomized Controlled Trial

Presenter: Matthew Reynolds, Benjamin Galper, Patricia Apruzzese, Joshua Walczak, Laura Mauri, Ted Feldman, Donald Glower, David Cohen

January 31, 2013

News Conference News TCT 2012

Extended EVEREST II Data Examine Safety, Efficacy of MitraClip as Well as Cost Effectiveness

October 25, 2012

Presentation TCT 2012

Lessons from EVEREST II

Presenter: Ted Feldman

October 24, 2012

Presentation TCT 2012

EVEREST II High Surgical Risk Cohort: Clinical Benefit by MR Grade in High Surgical Risk Patients One Year Following MitraClip Therapy.

Presenter: Paul Grayburn, Saibal Kar, Ted Feldman, Donald Glower, Elyse Foster, Laura Mauri

January 03, 2012

Advertisement

MitraClip G4 Data Impress, but Some Question the Reproducibility: EXPAND G4

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

Global EXPAND: Next-Gen MitraClip Cuts MR, Boosts QoL at 1 Year

DMR: EVEREST II Was a Decade Ago; Have MitraClip Techniques and Outcomes Improved?

How to Interpret Noninferiority Trials (eg, ABSORB III, EVEREST II, and Others)

Experts Debate Mitral Valve Repair, Replacement for Intermediate-Risk Patients

Five-Year Randomized EVEREST II Results: Where MitraClip Shined (and Where It Didnt)

Outcomes Following Percutaneous Reduction of Significant Mitral Regurgitation in EVEREST II High Risk Patients Who Were Symptomatic Despite Cardiac Resynchronization Therapy

Final 5-Year EVEREST II Results: Perspectives on What We Might Have Done Differently

Anatomic Criteria for the MitraClip: Are the Everest Criteria Just a Start?

TCT 788: Outcomes Following Percutaneous Reduction of Significant Mitral Regurgitation in EVEREST II High-Risk Patients Who Were Symptomatic Despite Cardiac Resynchronization Therapy

ACCESS-EUROPE, EVEREST II Data Support MitraClip in MR

TCT-85. Ventricular and Atrial Remodeling after the Percutaneous MitraClip: 4 year Follow-up Data from the EVEREST II Randomized Controlled Trial

TCT-89. Percutaneous Leaflet Therapy of Severe Primary Mitral Regurgitation: Totality of Evidence From the EVEREST II Randomized, Continued Access, and High Risk Clinical...

The EVEREST II Randomized Controlled Trial (RCT): Three Year Outcomes

Cost Effectiveness of the MitraClip® Compared with Mitral Valve Surgery: 12-month Results from the EVEREST II Randomized Controlled Trial

Extended EVEREST II Data Examine Safety, Efficacy of MitraClip as Well as Cost Effectiveness

Lessons from EVEREST II

EVEREST II High Surgical Risk Cohort: Clinical Benefit by MR Grade in High Surgical Risk Patients One Year Following MitraClip Therapy.

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content